Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone

Direct oral anticoagulants (DOACs) are not recommended in COVID-19 patients receiving dexamethasone because of potential drug-drug and drug-disease interactions affecting anticoagulant concentration and activity. To evaluate short- and long-term pharmacokinetic interactions, serial through and peak...

Descripción completa

Detalles Bibliográficos
Autores principales: Potere, Nicola, Candeloro, Matteo, Porreca, Ettore, Marinari, Stefano, Federici, Camilla, Auciello, Raffaella, Di Nisio, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425464/
https://www.ncbi.nlm.nih.gov/pubmed/34498156
http://dx.doi.org/10.1007/s11239-021-02561-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425464/
https://www.ncbi.nlm.nih.gov/pubmed/34498156
http://dx.doi.org/10.1007/s11239-021-02561-w

Ejemplares similares